Inhibikase Therapeutics Reports Third Quarter Financial Resu

BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course

Related Keywords

Boston , Massachusetts , United States , Copenhagen , Køavn , Denmark , Atlanta , Georgia , Alex Lobo , Risvodetinib Ik , Miltonh Werner , Company Contact , Exchange Commission , Youtube , Sternir Inc , Nasdaq , Inhibikase Therapeutics Inc , Linkedin , European Union , Facebook , Inhibikase Or Company , Movement Disorder Congress , Abelson Tyrosine Kinases , Chief Executive Officer , Multiple System , Upcoming Milestones , Orphan Drug Designation , Multiple System Atrophy , Abelson Tyrosine Kinase , Abelson Tyrosine , Private Securities Litigation Reform Act , Consolidated Statements , Comprehensive Loss , Months Ended September , Region ,